 To this end, patients with clinically significant spontaneous bleedings and who had their bleeding tendency reduced during the Phase 1 of the study without severe side effects, will be admitted to the Phase 2 of the study. During the Phase 2, patients will be treated with eltrombopag for 16 weeks. In order to determine the lowest dose of eltrombopag that is able to reduce or abolish their bleeding tendency, patients will start treatment with eltrombopag 25 mgday for 4 weeks. Then, every 4 weeks, patients will be re-evaluated and the dosage of eltrombopag will be adjusted according to the bleeding tendency of the 7 days before evaluation. The dosages of eltrombopag that can be used in the Phase 2 range from 12.5 to 75 mgday. 